About Urologix (OTCMKTS:ULGX)
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Electromedical equipment
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Urologix (OTCMKTS:ULGX) Frequently Asked Questions
What is Urologix's stock symbol?
Urologix trades on the OTCMKTS under the ticker symbol "ULGX."
How were Urologix's earnings last quarter?
Urologix (OTCMKTS:ULGX) released its quarterly earnings results on Thursday, February, 5th. The company reported ($0.02) EPS for the quarter. The business earned $3.10 million during the quarter, compared to the consensus estimate of $3.80 million. View Urologix's Earnings History.
Who are some of Urologix's key competitors?
Some companies that are related to Urologix include Medtronic (MDT), Varian Medical Systems (VAR), Sonova (SONVY), Masimo (MASI), LivaNova (LIVN), Getinge Group (GNGBY), CONMED (CNMD), NxStage (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT) and Fonar (FONR).
Who are Urologix's key executives?
Urologix's management team includes the folowing people:
- Bryon Merade, Chairman and Chief Exec. Officer
- Mr. Ash Keswani, Pres
Has Urologix been receiving favorable news coverage?
Press coverage about ULGX stock has trended somewhat negative on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Urologix earned a media sentiment score of -0.06 on Accern's scale. They also assigned news stories about the company an impact score of 44.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Urologix?
Shares of ULGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urologix's stock price today?
One share of ULGX stock can currently be purchased for approximately $0.0040.
How big of a company is Urologix?
Urologix has a market capitalization of $50,000.00.
How can I contact Urologix?
Urologix's mailing address is 14405 21ST AVE N, MINNEAPOLIS MN, 55447. The company can be reached via phone at 612-475-1400 or via email at [email protected]
MarketBeat Community Rating for Urologix (ULGX)MarketBeat's community ratings are surveys of what our community members think about Urologix and other stocks. Vote "Outperform" if you believe ULGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ULGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Urologix (OTCMKTS:ULGX) Analyst Ratings History
(Data available from 4/23/2016 forward)
Urologix (OTCMKTS:ULGX) Earnings History and Estimates Chart
Urologix (OTCMKTS ULGX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/12/2015||Q3 2015||($0.02)||$2.80 million||View||N/A|
|2/5/2015||Q215||($0.02)||$3.80 million||$3.10 million||View||Listen|
|11/4/2014||Q1 2015||($0.02)||$3.02 million||View||N/A|
|8/19/2014||Q4 14||($0.17)||$3.29 million||View||N/A|
|5/6/2014||Q3 2014||($0.08)||$3.36 million||View||N/A|
|10/29/2013||Q1 2014||($0.06)||$3.78 million||View||N/A|
|8/20/2013||Q4 2013||($0.05)||$4.18 million||View||N/A|
|5/1/2013||Q3 2013||($0.06)||($0.06)||$3.85 million||$4.08 million||View||N/A|
|11/14/2012||Q113||($0.06)||($0.05)||$4.48 million||$4.00 million||View||N/A|
Urologix (OTCMKTS:ULGX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Urologix (OTCMKTS ULGX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 0.28%
Urologix (OTCMKTS ULGX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/26/2013||Gregory Fluet||CEO||Buy||17,500||$0.31||$5,425.00|| |
|7/12/2013||Mitchell Dann||Director||Buy||20,000||$0.30||$6,000.00|| |
|7/10/2013||Gregory Fluet||CEO||Buy||25,000||$0.24||$6,000.00|| |
|7/9/2013||Lisa A Ackermann||EVP||Buy||18,500||$0.24||$4,440.00|| |
|7/8/2013||Gregory Fluet||CEO||Buy||66,400||$0.19||$12,616.00|| |
Urologix (OTCMKTS ULGX) News Headlines
Urologix (OTCMKTS:ULGX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Urologix (OTCMKTS:ULGX) Income Statement, Balance Sheet and Cash Flow Statement
Urologix (OTCMKTS ULGX) Stock Chart for Monday, April, 23, 2018